Raymond James Financial Increases Insulet (NASDAQ:PODD) Price Target to $385.00

Insulet (NASDAQ:PODD) had its price objective lifted by equities researchers at Raymond James Financial from $366.00 to $385.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James Financial’s target price indicates a potential upside of 16.25% from the stock’s current price.

A number of other research analysts have also issued reports on the stock. BTIG Research raised their target price on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research note on Friday. Piper Sandler lifted their price objective on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Stifel Nicolaus assumed coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective for the company. Leerink Partners raised their target price on Insulet from $355.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Wolfe Research lifted their price target on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $379.45.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $331.17 on Friday. The business’s 50-day simple moving average is $322.22 and its 200-day simple moving average is $315.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet has a 52 week low of $230.05 and a 52 week high of $354.88. The firm has a market cap of $23.30 billion, a price-to-earnings ratio of 100.66, a P/E/G ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter in the prior year, the business earned $1.08 earnings per share. The company’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Sage Mountain Advisors LLC boosted its holdings in Insulet by 4.6% during the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 33 shares in the last quarter. Glenmede Investment Management LP boosted its stake in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC grew its position in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the period. WINTON GROUP Ltd raised its stake in Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after acquiring an additional 37 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd lifted its holdings in shares of Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.